Merck's America's Diabetes Challenge: Get to Your Goals campaign is aimed at persuading patients to do what it takes to keep their blood sugar in check. Now, Merck is launching a similar campaign aimed at the Hispanic community, which is disproportionately affected by the disease.
No price war on hepatitis C drugs? That would be a disappointment to payers worried about the cost of treating millions of patients with super-expensive, yet highly effective drugs. But to investors, that reassurance sounds really good.
More than a couple of markets have been shaken up lately by new competition in oral form. And now, Sanofi's Genzyme is wondering if it can't make a splash of its own with Cerdelga, its newly approved pill for Gaucher disease.
New generic competition in the U.S. always makes a sales organization uneasy because layoffs usually follow. But Hospira's branded sales team faces a double whammy.
When surveyed about their outlook, pharma industry leaders said they felt plagued by uncertainty and beaten down by budget cuts. More than half worried they would receive pink slips by the end of this year. But some more optimistic execs predicted new investment in their departments, and many figured staffing levels will endure, at least for this year.
Celgene used a tried-and-true technique to persuade cost-effectiveness watchdogs to change their minds on Revlimid. The U.S.-based drugmaker capped its cost.
On Tuesday, Depomed announced that it won its patent lawsuit against Actavis, which wanted to market a generic version of Depomed's shingles pain drug Gralise. Depomed's shares surged more than 13% in after-hours trading to $14.94.
Allergan CEO David Pyott has hinted he might make a pickup to thwart Valeant's attempts to take over his company. And now that one-time target Shire is off the table after being snatched up by AbbVie, his sights may be set on Salix.
The sudden departure of a C-suite exec always raises eyebrows. When the company is a buyout target in the midst of a heated takeover battle, the questions really fly. But in the case of Allergan CFO Jeff Edwards, whose departure the company announced Monday, analysts say there's nothing to worry about.
Eli Lilly won't be able to sell its Lantus copycat--dubbed Basaglar--for at least 30 months because of a patent fight with Sanofi.
Merck's already won two bellwether suits over femur fractures suffered by Fosamax patients. But is that enough to get the remaining 500 or so cases tossed out?
Margins, margins, margins. That's an inevitable mantra among top investors and analysts. Just ask Novartis CEO Joe Jimenez, who's pledged big improvements in the Swiss drugmaker's spread. Or Eli Lilly CFO Derica Rice, who's had to explain why his company can promise to maintain margins as its sales spiral downward.
The U.S. Department of Justice closed out its probe of a key Brilinta trial--and without further ado. No additional label warnings. And certainly no forced withdrawal from the U.S. market.
As the FDA considers whether it should approve recently filed biosimilar versions of Johnson & Johnson's Remicade and Amgen's Neupogen, a parade of pharma companies, physicians and payers is coming forward to voice their concerns, not the least of which is how these products will be named. Now another group of concerned parties has joined the chorus: investors.
Valeant's tender offer for Allergan isn't expiring just yet. The company has extended the deadline to Dec. 31, giving it and activist investor partner Bill Ackman a few more months to go after deal-averse Allergan.
Biogen Idec has added another bow to its multiple sclerosis quiver. With the FDA's approval of Plegridy, a long-acting form of its popular Avonex, Biogen can fight for an even bigger share of the MS market.
What's that about Bart Becht's shadow? Don't ask Reckitt Benckiser CEO Rakesh Kapoor. He's not living in it.
Forget tax-advantaged Irish drugmakers. It may be a good time to take over an antibiotics maker on the cheap--and analysts have just the antibiotics maker in mind.
Ever since the FDA drafted a set of rules for biosimilars in 2012, a debate has been raging over whether those drugs should carry the same generic names as the products they emulate. Now, some doctors are weighing in on the issue, urging the FDA to require biosimilars to have different names than branded biotech drugs.
The Alabama Supreme Court won't back away from a controversial ruling against Pfizer, in a liability case closely watched by the rest of the pharma industry.